Psychedelic Medicine
March 28, 2026
Levi Neal, Hannah E. Shaw, Brenda M. Gannon et al.
Background: There are currently three FDA-approved medications for opioid use disorder (OUD), but none of them are especially effective, some can precipitate withdrawal in dependent individuals, and all of them require daily administration. In the appropriate settings, single administrations of psychedelics can elicit persistent anti-addiction effects in humans and in laboratory animals, but...
Journal of Psychopharmacology
2026
Jack E Henningfield, Sandra D Comer, Matthew L Banks et al.
5 citations
Abuse potential assessment of drugs with central nervous system activity is a critical component of the development of new medications for regulatory filings for approval worldwide. These new drug applications typically include recommendations for scheduling status as a controlled substance, if scheduling is warranted. This commentary focuses on the approach and current issues related to...
Journal of Pharmacology and Experimental Therapeutics
January 25, 2024
Hannah E. Shaw, D. R. Patel, Brenda M. Gannon et al.
Abuse of novel arylcyclohexylamines (ACX) poses risks for toxicities, including adverse neurocognitive effects. In vivo effects of ring-substituted analogs of phencyclidine (PCP), eticyclidine (PCE), and ketamine are understudied. Adult male National Institutes of Health Swiss mice were used to assess locomotor effects of PCP and its 3-OH, 3-MeO, 3-Cl, and 4-MeO analogs, PCE and its 3-OH and...
Drug and Alcohol Dependence
September 1, 2023
Brenda M. Gannon, Lauren R Fitzgerald, Christopher O Godwin et al.
Humans often administer psychostimulants in party or music festival settings characterized by warm ambient temperatures, which may impact drug effects; however, preclinical studies rarely investigate drug effects at multiple ambient temperatures. Work with 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) suggests that the presence of a 3,4-methylenedioxy ring...
Neuropharmacology
August 19, 2017
Michael D. Berquist, William S Hyatt, Jonathan J. Bauer-Erickson et al.
Methoxetamine (MXE) is a novel drug of abuse that is structurally similar to phencyclidine (PCP). In the present study, rats were trained to discriminate PCP from saline and substitution tests were performed with arylcyclohexylamines PCP, eticyclidine (PCE), tenocyclidine (TCP), and MXE. PCP and PCE engendered PCP-lever selection in all subjects, whereas MXE and TCP produced PCP-lever selection...
Neuroscience Letters
June 16, 2016
H. Rosas-Hernández, Elvis Cuevas, Susan M. Lantz et al.
Designer drugs such as synthetic psychostimulants are indicative of a worldwide problem of drug abuse and addiction. In addition to methamphetamine (METH), these drugs include 3,4- methylenedioxy-methamphetamine (MDMA) and commercial preparations of synthetic cathinones including 3,4-methylenedioxypyrovalerone (MDPV), typically referred to as “bath salts.” These psychostimulants exert...
The FASEB Journal
April 1, 2015
Brenda M. Gannon, Julia Tobacyk, William E Fantegrossi
Recently, there has been an increase in abuse of new synthetic psychostimulant drugs derived from the cathinone structure. These products are typically referred to as “bath salts”, and one of the most common psychoactive constituents of these preparations is 3,4‐methylenedioxypyrovalerone (MDPV). In these studies, we used the conditioned place preference (CPP) paradigm to explore the apparent...